EGFR and lung carcinoma: As inhibition of EGFR signaling was recognized as an important mechanism not only of zalutumumab, but also of other EGFR antibodies like cetuximab, we investigated the influence of (lung cancer-derived) mutations that change the EGFR kinase activity, on tumor cell killing [57] .An EGFR-responsive cell line model was established, in which cells expressed tumor-derived EGFR mutations (L858R, G719S, delE746-A750 and secondary mutation T790M).